The Disruptors: The Next Wave of Promising Psychiatry and Neurology Drugs

Grand Ballroom

Monday, June 12, 2023

2:00 PM - 2:40 PM

Disruptors

Watch Panel Here

Drugs that target the brain are among the most challenging to develop, yet they also signify an area of extraordinary unmet need. Driven by a deeper understanding of the complex biology of the human brain and the emergence of validated molecular targets for neuropsychiatric and neurodegenerative diseases, the field is beginning to make important strides. This panel will discuss the innovative drugs for conditions such as ALS, Alzheimer’s disease, schizophrenia, and depression that are now in and/or emerging from the drug development pipeline.

Moderators

Maurizio Fava, MD

Chair of Psychiatry, MGH;

Slater Family Professor of Psychiatry, HMS

Greg Harrison

Vice President, Global Research, BofA Securities

Panelists

Joshua Cohen

Co-CEO, Amylyx Pharmaceuticals

Steve Davis

CEO, Acadia Pharmaceuticals

Justin Klee

Co-CEO, Amylyx Pharmaceuticals

Ivana Magovcevic-Liebisch, PhD

President & CEO, Vigil Neuroscience

Vimal Mehta, MD

CEO, BioXcel Therapeutics